FDA NDA · NDA217064
RYZUMVI
Sponsor: FAMYGEN LIFE SCI
What this page does not claim
A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.
APPLICATION
NDA217064
TYPE
NDA
ORIGINAL APPROVAL
2023-09-25
LATEST ACTION
2026-10-16
ROUTE
OPHTHALMIC
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription
Products
RYZUMVI · ReferencePrescription
PHENTOLAMINE MESYLATE EQ 0.75% BASE · SOLUTION · OPHTHALMIC
Approval history
Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →